[What is the position of bariatric surgery in the treatment of non-alcoholic steatohepatitis?]

Presse Med. 2019 Dec;48(12):1502-1506. doi: 10.1016/j.lpm.2019.09.016. Epub 2019 Nov 19.
[Article in French]

Abstract

Bariatric surgery is indicated for patients with BMI≥35kg/m2 and associated steatohepatitis. Bariatric surgery induces NASH disappearance for nearly 80% of patients after 1 year of follow up. Bariatric surgery is associated with low morbidity and mortality if patients are well selected. Bariatric surgery is contraindicated in patients with cirrhosis. Long-term data are needed to determine the risk of recurrence of NASH. The extension of indications for bariatric surgery to patients with BMI less than 35kg/m2 will depend on the results of randomized trials.

Publication types

  • Review

MeSH terms

  • Bariatric Surgery* / adverse effects
  • Bariatric Surgery* / classification
  • Bariatric Surgery* / methods
  • Bariatric Surgery* / trends
  • Humans
  • Non-alcoholic Fatty Liver Disease / epidemiology
  • Non-alcoholic Fatty Liver Disease / etiology
  • Non-alcoholic Fatty Liver Disease / surgery*
  • Postoperative Care / methods